NLS Pharmaceutics to Participate in The Micro Cap Rodeo Fall Harvest Conference: Best Ideas from the Buy-side
NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW), a Swiss clinical-stage pharmaceutical company, is set to present at The Micro Cap Rodeo Fall Harvest Conference from October 5-8, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW), a Swiss clinical-stage pharmaceutical company, is set to present at The Micro Cap Rodeo Fall Harvest Conference from October 5-8, 2021. CEO Alex Zwyer will provide a corporate overview on October 5 at 9:00 am ET. The presentation is accessible through a provided link, and a replay will be available on the company's website. NLS's lead candidate, Quilience, is in phase 2 studies for narcolepsy treatment and has received Orphan Drug Designations in the U.S. and Europe.
Details
News Market Reaction – NLSP
The recorded move for NLSP in the trading session of this news was -0.79%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
STANS, SWITZERLAND / ACCESSWIRE / September 30, 2021 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that its Chief Executive Officer and Co-Founder Alex Zwyer is scheduled to present a corporate overview and meet with investors at The Micro Cap Rodeo Fall Harvest Conference to be held virtually October 5-8, 2021.
Event Details:
Date: October 5, 2021
Time: 9:00am ET
Event Access: Please click this link to access the NLS presentation. A replay will also be available on Company's website at https://nls-pharma.com/
About NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd. is a Swiss clinical-stage biopharmaceutical company led by an experienced management team with a track record of developing and repurposing product candidates to treat rare and complex central nervous system disorders. The Company's lead product candidate, Quilience® is a proprietary extended-release formulation of mazindol (mazindol ER) and is being developed for the treatment of narcolepsy. Mazindol is a triple monoamine reuptake inhibitor and partial orexin-2 receptor agonist, which was used for many years to treat patients diagnosed with narcolepsy in compassionate use programs. NLS has recently initiated a phase 2 study in the U.S. evaluating Quilience® in adult subjects suffering from Narcolepsy. Previously, NLS successfully completed a phase 2 study in the U.S. evaluating Nolazol® (mazindol controlled-release) in adult subjects suffering from ADHD. The study met all primary and secondary endpoints and Nolazol® was well-tolerated. Quilience® has received Orphan Drug Designations both in the U.S. and in Europe for the treatment of narcolepsy. Up to 1/3rd of narcoleptic patients are also diagnosed with ADHD.
Corporate contact
Alex Zwyer, CEO: +41 41 618 80 00
Investor Relations contact
Cindy Rizzo: +1 908-229-7050
SOURCE: NLS Pharmaceutics AG
View source version on accesswire.com:
https://www.accesswire.com/666124/NLS-Pharmaceutics-to-Participate-in-The-Micro-Cap-Rodeo-Fall-Harvest-Conference-Best-Ideas-from-the-Buy-side
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.